Organization | Fujian Cosunter Pharmaceutical Co. Ltd

Fujian Cosunter Pharmaceutical Co. Ltd Report issue

For profit Phase 1 Phase 4

Founded: Fuzhou China (2001)

Status: No NME R&D (2001)

Organization Overview

First Clinical Trial

2011

NCT01436539

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Fujian Cosunter Pharmaceutical Co. Ltd

Active Ingredients

Drugs in Phase 4 Trials (6)

adefovir dipivoxil (hepsera) (1 trial)

aldesleukin (proleukin) (1 trial)

entecavir (baraclude) (1 trial)

hepatitis b vaccine (recombinant) (recombivax) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

polyene phosphatidylcholine (1 trial)

Drugs in Phase 1 Trials (3)

gst-hg131 (1 trial)

gst-hg141 (2 trials)

gst-hg161 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 9